Editas Medicine Inc
EDIT
ISIN null / Valor 30992799
Editas Medicine Inc
UMushroom community rating:
About company
Editas Medicine Inc. is a Cambridge, Massachusetts–based biotechnology company founded in 2013 that develops therapeutic medicines using CRISPR-based genome editing tools and delivery technologies to target genetic diseases. The company pursues both in vivo and ex vivo approaches, with a pipeline that includes clinical-stage programs for inherited retinal disorders and earlier-stage programs aimed at other monogenic and hematologic conditions, and it advances assets through internal research, clinical development and partnerships. As a development-stage biopharma, Editas generates little product revenue and relies on collaboration deals, grants and capital markets to fund costly R&D and clinical trials, leaving its prospects closely tied to clinical results, regulatory review and the practical challenges of safe and effective gene editing delivery.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
465 M
Market cap (USD)
2,276,227
Daily traded volume (Shares)
1.265 / 1.175
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Marc Bareth
EQUITIES OF THE SAME SECTOR
